Summary of minutes of EUCAST Steering Committee Meeting
Basel, Switzerland, 22-23 November 2010

Attending
Dr Petra Apfalter PA EUCAST Austria
Dr Derek F.J. Brown DB Scientific Secretary United Kingdom
Dr Rafael Canton RC Clinical Data Co-ordinator Spain
Dr Christian Giske CG SRGA Sweden
Dr Marina Ivanova MI EUCAST Estonia
Prof Gunnar Kahlmeter GK Chairperson Sweden
Prof Alasdair P. MacGowan AM BSAC United Kingdom
Dr Johan W. Mouton JM CRG The Netherlands
Prof Arne Rodloff AR DIN Germany
Prof Claude-James Soussy CS CA-SFM France
Dr Martin Steinbakk MS NWGA Norway
Present for item 6
Dr Muhamed-Kheir Taha MT EMGM France

1 Chairman’s welcome

2 Minutes of meeting of 26-27 Sept 2010 The minutes were accepted as a correct record.

3 Matters arising from minutes of 26-27 September 2010
A paper for CMI explaining ECOFFs is to be prepared.

MIC data on anaerobes is to be added to the MIC database.

EUCAST breakpoints are available for all agents in the EARS-Net surveillance programme.

Implications of changing breakpoints on resistance surveillance data were discussed.

EUCAST SOPs for the breakpoint setting procedure have been published on the EUCAST website.

Rifampicin, trimethoprim and fusidic acid rationale documents have been released.

A EUCAST document on antiviral resistance surveillance has been sent to ECDC.

4 New agents
A new glycopeptide is in progress at EMA and a new cephalosporin is likely to be submitted in 2011.

5 Status of EUCAST rationale documents The current status of several documents was reviewed and several drafts were updated.

6 Meningococcal breakpoints MT presented the views of the European Monitoring Group on Meningococci (EMGM) and, following discussion, it was agreed that the two groups would continue to collaborate on breakpoint setting for meningococci.

7 Expert rules subcommittee Discrepancies between the breakpoint tables and expert rules are being resolved before publication of version 2. Expert rules software will be updated before release.

8 Antifungal susceptibility testing subcommittee There will be changes to the subcommittee in May 2011. Several rationale documents are close to completion.

9 Anaerobe subcommittee The anaerobe methods study is still in progress.

10 Organisms without EUCAST breakpoints Discussions with the European Helicobacter working group are continuing. Following discussions with the European C. difficile study group, breakpoints/ECOFFs will be sent for consultation. Work on several other groups of organisms is underway.
<table>
<thead>
<tr>
<th></th>
<th><strong>ESC MID</strong></th>
<th>The Postgraduate Educational Course in Madrid in September 2010 was successful and the next course will probably be organised in 2012.</th>
</tr>
</thead>
<tbody>
<tr>
<td>12</td>
<td><strong>EMA</strong></td>
<td>No new information.</td>
</tr>
<tr>
<td>13</td>
<td><strong>CLSI</strong></td>
<td>No new information.</td>
</tr>
<tr>
<td>14</td>
<td><strong>ECDC</strong></td>
<td>The future organisation of the Steering Committee and the General Committee to accommodate changes following adoption of EUCAST breakpoints and increasing interest from outside Europe were discussed.</td>
</tr>
<tr>
<td>15</td>
<td><strong>Implementation of EUCAST breakpoints</strong></td>
<td>The international adoption of EUCAST breakpoints and the disk diffusion method were reviewed. Several disk diffusion development projects are underway. The EUCAST website tables detailing manufacturers’ readiness for EUCAST breakpoints and methods have been expanded and updated. The updated version of the breakpoint tables will be released before the end of 2010. All <em>Moraxella catarrhalis</em> breakpoints were reviewed and proposed changes will be sent for wide consultation.</td>
</tr>
<tr>
<td>16</td>
<td><strong>Agents without breakpoints</strong></td>
<td>No cefazolin breakpoints will be proposed for Enterobacteriaceae unless there are specific indications that breakpoints are needed. There was extensive discussion on use of nalidixic acid for screening for quinolone resistance and future changes to breakpoint tables will be required. Cefradine and cefalothin ECOFFs will be provided.</td>
</tr>
<tr>
<td>17</td>
<td><strong>Website</strong></td>
<td>A note on the Q&amp;A section has been added to the News section.</td>
</tr>
<tr>
<td>18</td>
<td><strong>Any other business</strong></td>
<td>Cefixime breakpoints for <em>N. gonorrhoeae</em>, EUCAST breakpoints splitting wild type, and direct susceptibility tests will be reviewed at the next meeting. A computer program for calculating ECOFFs generally gives results in line with current ECOFFs.</td>
</tr>
</tbody>
</table>

Ratified summary of minutes of meeting 22-23 November 2010. Prepared by DB, GK and RC